HARBI1 Inhibitors
HARBI1 Inhibitors encompass a variety of chemical compounds that act on specific signaling pathways which can lead to the indirect inhibition of HARBI1 activity. Staurosporine, for example, is a powerful kinase inhibitor affecting a wide range of kinases. In the context of HARBI1, the inhibition of these kinases by staurosporine could lead to a reduction in HARBI1 activity, as kinase signaling is often essential for the phosphorylation-dependent activation of many proteins, including HARBI1. Similarly, LY294002 and Wortmannin are inhibitors of the PI3K pathway, which is a critical regulator of cell survival and proliferation. The inhibition of PI3K by these compounds would attenuate Akt signaling, a downstream effector that may be necessary for HARBI1 activation. As such, the reduction in PI3K/Akt signaling could lead to a decrease in HARBI1 activity.
Furthermore, U0126 and PD98059 are selective inhibitors of MEK, a kinase within the MAPK/ERK pathway. The MAPK/ERK pathway is a key signaling cascade involved in cell growth and differentiation. Inhibition of this pathway would prevent the phosphorylation and activation of ERK, potentially reducing HARBI1 activity if HARBI1 is activated downstream of ERK. Rapamycin, an mTOR inhibitor, and SB203580, a p38 MAP kinaseinhibitor, exert their effects on the mTOR and p38 MAP kinase pathways, respectively. Reduced mTOR signaling due to rapamycin administration could lead to a decrease in HARBI1 function, as mTOR is a central regulator of cellular metabolism, growth, and proliferation, which may intersect with HARBI1 regulatory mechanisms. SB203580's inhibition of p38 MAP kinase would similarly decrease HARBI1 activity if HARBI1 operates downstream of this specific MAPK pathway.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that targets a wide range of kinases. By inhibiting protein kinases that are upstream activators of HARBI1, staurosporine can decrease HARBI1 activity through reduced phosphorylation and activation of HARBI1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of the PI3K/Akt pathway. Since HARBI1 activity can be modulated by the PI3K/Akt signaling, LY294002 inhibits this pathway, potentially leading to decreased activation of HARBI1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another inhibitor of the PI3K pathway. By inhibiting PI3K, wortmannin can prevent the downstream activation of Akt and subsequently reduce the activation of HARBI1 that may be Akt-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2, which are kinases in the MAPK/ERK pathway. Inhibition by U0126 can prevent ERK activation, which may be necessary for the activation of HARBI1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that acts by binding to FKBP12 and the resulting complex inhibits mTORC1. Reduced mTOR activity can lead to a decrease in HARBI1 function, as mTOR signaling is potentially a regulator of HARBI1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the JNK signaling pathway. JNK regulates a variety of cellular functions, and its inhibition by SP600125 can decrease HARBI1 activity if HARBI1 is a downstream effector of JNK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which blocks the activation of MAPK/ERK. By inhibiting MEK, PD98059 can reduce HARBI1 activity if HARBI1 is downstream of the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A specific inhibitor of p38 MAP kinase. By blocking p38 MAP kinase activity, SB203580 can lead to decreased HARBI1 activity if HARBI1 operates downstream of the p38 MAPK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A selective inhibitor of Src family kinases. Src kinases can regulate various signaling pathways, and their inhibition by PP2 may result in reduced activation of HARBI1 if Src kinases facilitate HARBI1 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A multi-kinase inhibitor that targets RAF kinases, among others. By inhibiting RAF, Sorafenib can reduce HARBI1 activity, assuming HARBI1 is downstream of the RAF/MEK/ERK signaling pathway. | ||||||